| Theme | Chronic kidney disease-mineral and bone disorder (CKD-MBD) guidelines: Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) 2017 CKD-MBD Guidelines Update | |
|---|---|---|
| Title | Bone disorders in CKD patients | |
| Publish Date | 2018/06 | |
| Author | Senji Okuno | Department of Internal Medicine, Shirasagi Hospital |
| Author | Masaaki Inaba | Department of Metabolism, Endocrinology and Molecular Medicine, and Department of Nephrology, Osaka City University Graduate School of Medicine |
| [ Summary ] | It is well established that patients with chronic kidney disease (CKD) have increased fracture rates compared to the general population. These fractures are associated with increased morbidity and mortality. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline suggests that bone mineral density (BMD) assessment is reasonable if results will impact treatment decisions, in patients with CKD G3a-G5d with evidence of CKD-MBD and/or risk factors for osteoporosis. Because experience with osteoporosis medications for patients with CKD is accumulating, the usefulness of these drugs has been recognized. However, it is still prudent that these drugs be used with caution and that the underlying renal osteodystrophy be addressed first. | |